Evidence map›Paper›PMID 39773010›Full record

ArticleHuman vaccines & immunotherapeutics2025

Global research trends on biomarkers for cancer immunotherapy: Visualization and bibliometric analysis.

Yuan Qiao, Dong Xie, Zhengxiang Li, Shaohua Cao, Dong Zhao

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Current Status of Immunotherapy in Resectable Lung Cancer.Indian journal of surgical oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuan QiaoDepartment of Clinical Pharmacy, Yan'an University Affiliated Hospital, Yan'an, Shaanxi, China.
Dong XieDepartment of Pharmacy, Tianjin Medical University General Hospital, Tianjin, China.
Zhengxiang LiDepartment of Pharmacy, Tianjin Medical University General Hospital, Tianjin, China.
Shaohua CaoDepartment of Clinical Pharmacy, Yan'an University Affiliated Hospital, Yan'an, Shaanxi, China.
Dong ZhaoDepartment of Clinical Laboratory, Yan'an University Affiliated Hospital, Yan'an, Shaanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global burden of cancer continues to grow, posing a significant public health challenge. Although cancer immunotherapy has shown significant efficacy, the response rate is not high. Therefore, the objective of our research was to identify the latest research trends and hotspots on biomarkers from 1993 to 2023. Data were collected from the database Web of Science core collection. Bibliometric analysis and visualization were conducted with CiteSpace(6.3.1), VOSviewer (v1.6.20), R-bibliometrix(v4.3.3), and Microsoft Excel(2019). A total of 2686 literatures were retrieved. The sheer annual volume of publications has shown a rapid upward trend since 2015. The United States has generated the most publications and Harvard University ranked as a leading institution. The global biomarker research on immune checkpoint inhibitors (ICIs) revealed regional differences and in-depth explorations should be promoted in developing countries. Although China has become the second largest country in terms of publication, the average citation per paper and the total link strength were both lower than the other countries. The research on biomarkers mainly concentrated upon the following aspects: PD-1/PD-L1, CTLA-4, gene expression, adverse events, total mutational burden (TMB), body mass index (BMI), gut microbiota, cd8(+)/cd4(+) t-cells, and blood-related biomarkers such as lactate dehydrogenase (LDH), neutrophil-lymphocyte ratio (NLR), cytokines. Furthermore, "artificial intelligence" and "machine learning" have become the most important research hotspot over the last 2 y, which will help us to identify useful biomarkers from complex big data and provide a basis for precise medicine for malignant tumors.

Indexed as

BibliometricsBiomarkers, TumorImmunotherapyNeoplasmsB7-H1 AntigenBiomedical ResearchCTLA-4 AntigenHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorB7-H1 AntigenBiomarkers, TumorCTLA-4 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorbibliometricsBiomarkerscancerimmune checkpoint inhibitorimmunotherapyvisualization analysis

Identifiers

PMID39773010
PMCPMC11730411

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.